| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ABEO Overview
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases.
Abeona Therapeutics Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.90 |
| 52 Week High | US$0.84 |
| 52 Week Low | US$3.79 |
| Beta | 1.52 |
| 1 Month Change | -25.10% |
| 3 Month Change | -33.42% |
| 1 Year Change | -31.91% |
| 3 Year Change | -90.44% |
| 5 Year Change | -88.77% |
| Change since IPO | -99.98% |
Recent News & Updates
Here's Why Abeona Therapeutics (NASDAQ:ABEO) Can Manage Its Debt Despite Losing Money
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Shareholder Returns
| ABEO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.2% | 1.7% | 4.0% |
| 1Y | -31.9% | 15.6% | 30.5% |
Return vs Industry: ABEO underperformed the US Biotechs industry which returned 13.6% over the past year.
Return vs Market: ABEO underperformed the US Market which returned 30% over the past year.
Price Volatility
| ABEO volatility | |
|---|---|
| ABEO Beta | 1.52 |
| Industry Beta | 0.98 |
| Market Beta | 1 |
Stable Share Price: ABEO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: ABEO's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1974 | 76 | Michael Amoroso | https://www.abeonatherapeutics.com |
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs.
Abeona Therapeutics Fundamentals Summary
| ABEO fundamental statistics | |
|---|---|
| Market Cap | US$90.98m |
| Earnings (TTM) | -US$54.27m |
| Revenue (TTM) | US$10.00m |
9.1x
P/S Ratio-1.7x
P/E RatioIs ABEO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABEO income statement (TTM) | |
|---|---|
| Revenue | US$10.00m |
| Cost of Revenue | US$31.86m |
| Gross Profit | -US$21.86m |
| Expenses | US$32.42m |
| Earnings | -US$54.27m |
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.54 |
| Gross Margin | -218.58% |
| Net Profit Margin | -542.74% |
| Debt/Equity Ratio | 2.1% |
How did ABEO perform over the long term?
See historical performance and comparisonValuation
Is Abeona Therapeutics undervalued compared to its fair value and its price relative to the market?
1.08x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ABEO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ABEO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ABEO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ABEO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ABEO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ABEO is good value based on its PB Ratio (1.1x) compared to the US Biotechs industry average (2.9x).
Future Growth
How is Abeona Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
40.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ABEO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ABEO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ABEO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ABEO's revenue (80.5% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: ABEO's revenue (80.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ABEO's Return on Equity is forecast to be high in 3 years time
Past Performance
How has Abeona Therapeutics performed over the past 5 years?
-28.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ABEO is currently unprofitable.
Growing Profit Margin: ABEO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ABEO is unprofitable, and losses have increased over the past 5 years at a rate of 28.2% per year.
Accelerating Growth: Unable to compare ABEO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ABEO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: ABEO has a negative Return on Equity (-64.55%), as it is currently unprofitable.
Financial Health
How is Abeona Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: ABEO's short term assets ($78.9M) exceed its short term liabilities ($41.9M).
Long Term Liabilities: ABEO's short term assets ($78.9M) exceed its long term liabilities ($4.7M).
Debt to Equity History and Analysis
Debt Level: ABEO's debt to equity ratio (2.1%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if ABEO's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ABEO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ABEO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 27.3% each year
Dividend
What is Abeona Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ABEO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ABEO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ABEO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ABEO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ABEO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
0.4yrs
Average management tenure
CEO
Michael Amoroso (43 yo)
0.92
Tenure
US$1,737,947
Compensation
Mr. Michael Amoroso serves as President and Director at Abeona Therapeutics Inc. since March 19, 2021 and Chief Executive Officer since November 01, 2020. Mr. Amoroso served as Chief Operating Officer of A...
CEO Compensation Analysis
Compensation vs Market: Michael's total compensation ($USD1.74M) is above average for companies of similar size in the US market ($USD545.22K).
Compensation vs Earnings: Insufficient data to compare Michael's compensation with company performance.
Leadership Team
Experienced Management: ABEO's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.
Board Members
Experienced Board: ABEO's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ABEO insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.4%.
Top Shareholders
Company Information
Abeona Therapeutics Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Abeona Therapeutics Inc.
- Ticker: ABEO
- Exchange: NasdaqCM
- Founded: 1974
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$90.983m
- Shares outstanding: 101.23m
- Website: https://www.abeonatherapeutics.com
Number of Employees
Location
- Abeona Therapeutics Inc.
- 1330 Avenue of the Americas
- 33rd Floor
- New York
- New York
- 10019
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/10/19 23:37 |
| End of Day Share Price | 2021/10/19 00:00 |
| Earnings | 2021/06/30 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.